administrator Site Admin
Joined: 28 Dec 2005 Posts: 11987
|
Posted: Fri Aug 24, 2007 6:04 pm Post subject: Quarterly Update |
|
|
Quarterly Update:
This portfolio began May 1st. Shares of CTIC fell, were bought, and rose to recover most or all of the early losses. CRIS has been a loser, while DNDN and XOMA are roughly neutral. CTIC and DNDN may have the most upside potential, given the quality of their pending drugs. However, I'm sure, there's a better biotech out there that I haven't found yet. Nonetheless, these biotechs have the potential to rise sharply, and quickly, by the end of the year, although XOMA was bought only for a short-term trade.
My portfolio is about $100,000, including about $60,000 in cash.
Shares Long or Call Options
CTIC 5,000 Shares
CRIS 3,000 Shares
XOMA 3,000 Shares
DNDN Jan 7.5 2008 100
DNDN Jan 10 2008 100
Shares Short or Put Options
None
Margin portfolio at $100,000 on May 1st, 2007.
24. S 2,000 shares CTIC $7,800
23. B 2,000 shares CTIC $6,900
22. B 50 DNDN Jan 10 calls $1,250
21. B 50 DNDN Jan 7.5 calls $3,000
20. B 3,000 shares XOMA $6,300
19. B 2,000 shares CTIC $7,800
18. B 50 DNDN Jan 7.5 calls $4,000
17. S 1,000 shares CTIC $4,900
16. S 2,000 shares CTIC $9,300
15. B 2,000 shares CTIC $8,000
14. S 2,000 shares CTIC $9,200
13. B 50 DNDN Jan 10 calls $3,000
12. S 2,000 shares CTIC $8,400
11. S 2,000 shares CTIC $8,400
10. B 3,000 shares CRIS $3,600
9. S 2,000 shares CTIC $7,400
8. S 2,000 shares CTIC $7,000
7. B 2,000 shares CTIC $6,200
6. B 2,000 shares CTIC $7,000
5. B 2,000 shares CTIC $7,600
4. B 2,000 shares CTIC $8,300
3. B 2,000 shares CTIC $9,500
2. B 2,000 shares CTIC $9,700
1. B 2,000 shares CTIC $11,000 |
|